Looking at the universe of stocks we cover at Dividend Channel, on 9/14/17, Utah Medical Products, Inc. (UTMD - Get Report) will trade ex-dividend, for its quarterly dividend of $0.265, payable on 10/3/17. As a percentage of UTMD's recent stock price of $73.05, this dividend works out to approximately 0.36%.Below is a dividend history chart for UTMD, showing historical dividends prior to the most recent $0.265 declared by Utah Medical Products, Inc.: In general, dividends are not always predictable; but looking at the history above can help in judging whether the most recent dividend from UTMD is likely to continue, and whether the current estimated yield of 1.45% on annualized basis is a reasonable expectation of annual yield going forward. The chart below shows the one year performance of UTMD shares, versus its 200 day moving average: Looking at the chart above, UTMD's low point in its 52 week range is $56.30 per share, with $75.00 as the 52 week high point — that compares with a last trade of $73.05. In Tuesday trading, Utah Medical Products, Inc. shares are currently down about 0.1% on the day.
TheStreet’s Fundamentals of Investing Course will teach you the keys to making the right decisions in any market.
TheStreet’s Personal Finance Essentials Course will teach you money management basics and investing strategies to help you avoid major financial pitfalls.
TheStreet Courses offers dedicated classes designed to improve your investing skills, stock market knowledge and money management capabilities.
More from Stocks
Financial Market Behavior, General Mills Earnings: Market Recon
Markets must choose now between the easy, the tense and the uncertain. What could possibly go wrong?
Del Frisco's to Be Acquired for $650 Million by Private-Equity Firm L Catterton
Del Frisco's is being acquired by private-equity firm L Catterton for $8 a share.
Bristol-Myers Plans Otezla Sale to Win FTC Approval for $74 Billion Celgene Deal
Bristol-Myers Squibb shares slumped lower in pre-market trading Monday after the group said the U.S. Federal Trade Commission was still looking into its proposed $74 billion takeover of cancer specialist Celgene and that it would sell that company's psoriasis to push the deal through.